Sign in
TerminatedPhase 3

Stop Retinal Ganglion Cell Dysfunction Study

Key facts

Who runs it
University of Miami
Where
Miami, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 3
People taking part
28 people enrolled
Started
Sept 2015
Ended
4 Oct 2024
Type of study
Interventional, 3 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Latanoprost
  • Bimatoprost
  • Travoprost
  • Timolol
  • Dorzolamide
  • Brinzolamide
  • Acetazolamide
  • Methazolamide
Record updated
26 August 2025
Why it stopped
No patients had abnormal PERG and could not be included in the first two arms from the baseline timepoint.

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age 18 to 85 years, inclusive
  • Refractive errors within -5 to +3 diopters
  • Best corrected visual acuity (BCVA) better than or equal to 20/30 (Snellen)
  • Normal standard automated perimetry (SAP) according to the Ocular Hypertension Treatment Study (OHTS) criteria15 (reliability < 15% on all indices, normality > 5% on all global indices in two consecutive sessions 6 months apart)
  • Minimum untreated Intraocular pressure IOP of 15 mm Hg
  • Glaucoma Suspect Status defined as one or more of the following:; Glaucomatous optic disc appearance (vertical cup-to-disc ratio [C/D] ≥0.5; Cup disc ratio asymmetry ≥0.2; Localized thinning of the disc; Presence or history of splinter disc hemorrhage; Moderately increased IOP (>21 to <28 mm Hg); Family history of vision loss for glaucoma

Who cannot take part

  • Currently using prescribed pressure lowering medicines and unwilling to be withdrawn from them
  • Diabetes
  • Parkinson's disease
  • Age-related macular degeneration
  • Multiple sclerosis
  • Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits
  • Pregnant or nursing women
  • An OHTS risk score high enough in the judgment of the ophthalmologist or optometrist managing the patient to recommend pressure lowering medicine to the patient and not randomization
  • An OCT abnormal enough in a pattern consistent with glaucoma

Where in United States

  • Bascom Palmer Eye Institute - University of MiamiMiami, United States

About the trial

What the trial wants to find out

Glaucoma is a progressive disease resulting in blindness. Determining the onset of the disease, predicting its severity and the benefit of pressure lowering eye drops is key to clinical management aimed at maintaining useful vision with advancing age. This study will longitudinally monitor a population of glaucoma suspects (with positive factors for the disease but with normal vision) with noninvasive pattern electroretinogram (PERG) and other standard eye tests for glaucoma. The PERG measures the function of retinal ganglion cells (RGCs) that are the parent neurons of the optic nerve. RGCs may become dysfunctional before dying and their function restored with pressure-lowering eye drops. Glaucoma suspects with abnormal PERG will be randomized to treatment with eye drops, while those with normal PERG will be left untreated. All patients will be monitored with PERG, Optic Coherence Tomography (OCT) and other ancillary tests every 6 months over 4 years.

The 3 groups in the trial

  • Abnormal PERG UntreatedNo study treatment, for comparison

    Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to not receive therapy or intervention.

  • Abnormal PERG TreatedTreatment being tested

    Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to receive one or more drops in each eye in order to reduce the intraocular pressure by 20%. Drugs could be: Latanoprost 1 drop Once a day (QD) Bimatoprost 1 drop QD Travoprost 1 drop QD Timolol 1 drop Twice a day (BID) Dorzolamide 1 drop Three times a day (TID) Brinzolamide 1 drop BID Acetazolamide and Methazolamide depends on clinicians evaluation. If Clinicians consider necessary, he/she might combine 2 drugs in order to get the desired intraocular pressure.

    Treatment: Latanoprost, Bimatoprost, Travoprost, Timolol, Dorzolamide, Brinzolamide, Acetazolamide, and Methazolamide

  • NormalNo study treatment, for comparison

    Patients with a normal PERG test that will go through the study under observation.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
26 August 2025